TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06976606: A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM

Sponsor: Lexeo Therapeutics · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 40 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,095,600

Rescue Site Savings

+$730,400

Unlock Full NCT06976606 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06976606 Rescue Dossier →